Impact of Inversion of the CD4/CD8 Ratio on the Natural History of HIV-1 Infection
- 15 August 2006
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in JAIDS Journal of Acquired Immune Deficiency Syndromes
- Vol. 42 (5), 620-626
- https://doi.org/10.1097/01.qai.0000223028.55080.9d
Abstract
HIV-1 infection is characterized by an inverted CD4/CD8 T-cell ratio, but the distribution of inversions over time after seroconversion and whether delay of inversion is associated with a favorable prognosis are not known. T-cell counts and clinical outcomes among men in the Multicenter AIDS Cohort Study who had incident HIV-1 infection before December 31, 1995 were analyzed by Kaplan-Meier and Cox proportional hazards methods. Results were also analyzed by time-dependent multivariate methods to adjust for CD4 lymphocyte counts, viral loads, age, race, and polymorphisms in host chemokine receptor genes (CCR5-Δ32 and CCR2-64I). Among 424 cases whose date of seroconversion was known to within ±4.5 months, 317, 52, and 55 inverted their CD4/CD8 ratio within less than 1, 1 to 2, and more than 2 years of seroconversion, respectively. Longer time to inversion was significantly associated with longer time to AIDS, even after adjusting for CD4 lymphocyte count and viral load at the first seropositive visit and over the first 3 seropositive visits. Of the 6 seroconverters who had more than 500 CD4 lymphocytes 10 years after seroconversion without receiving highly active antiretroviral therapy, 5 took more than 2 years to invert their CD4/CD8 ratio. Time from HIV-1 seroconversion to inversion of the CD4/CD8 ratio independently predicted time to AIDS. Early measurements of the CD4/CD8 ratio until inversion occurs may identify people likely to become long-term nonprogressors or slow progressors, thus facilitating detailed studies of the mechanism of HIV-1 disease progression.Keywords
This publication has 15 references indexed in Scilit:
- Determinants of clinical progression in antiretroviral‐naïve HIV‐infected patients starting highly active antiretroviral therapy. Aquitaine Cohort, France, 1996–2002HIV Medicine, 2005
- The effect of genetic variation in chemokines and their receptorson HIV transmission and progression to AIDSImmunological Reviews, 2000
- Natural History of Human Immunodeficiency Virus Type 1 Viremia after Seroconversion and Proximal to AIDS in a Large Cohort of Homosexual MenThe Journal of Infectious Diseases, 2000
- Plasma Viral Load and CD4+ Lymphocytes as Prognostic Markers of HIV-1 InfectionAnnals of Internal Medicine, 1997
- CD4:CD8 ratio and HIV infection: the ‘tap-and-drain’ hypothesisImmunology Today, 1996
- Genetic control of the CD4/CD8 T-cell ratio in humansNature Medicine, 1995
- The Multicenter AIDS Cohort Study: Retention after 9½ YearsAmerican Journal of Epidemiology, 1995
- Evaluation of a dual‐color flow cytometry immunophenotyping panel in a multicenter quality assurance programCytometry, 1993
- Quality control in the flow cytometric measurement of T-lymphocyte subsets: The Multicenter AIDS Cohort Study experienceClinical Immunology and Immunopathology, 1990
- THE MULTICENTER AIDS COHORT STUDY: RATIONALE, ORGANIZATION, AND SELECTED CHARACTERISTICS OF THE PARTICIPANTSAmerican Journal of Epidemiology, 1987